Recording Date: August 10, 2011
Duration: 1 hr 51 min
Price: $199*

Click here to download the order form or call 484-324-2755.

Agenda & Speakers

•Fosamax: What it is used for, its effectiveness and frequency of use
•Analyzing the “the Fosamax induced femur fracture”
-Low impact fractures accompanied with the use of Fosamax and other bishphosphonate drugs
-Causation issues, if any
-Studies to date, including manufacturer studies and trials: What Merck knew and when
-FDA warnings and actions to date
•Case theories and defense responses
-Design defect
-Failure to warn
-Marketing machine: The marketing of a non-disease

•Damages: Scope of treatment & rehabilitation, essential documents & records, & required experts
•Case selection, projections and settlement options
•State and MDL Intersection:
-What is happening in FL and CA: Major cases and discovery concerns
-The Fosamax MDL-The path ahead with Honorable Garrett Brown
-The number of cases to date, including those to be consolidated
-State and MDL coordination-Opportunities and challenges
•Will generic drugs be a factor?

Faculty:
Karen Barth Menzies, Esq., Robinson, Calcagnie & Robinson, Newport Beach, CA
J. Paul Sizemore, Esq., Sizemore Law Firm, PLC, El Segundo, CA
Victoria Maniatis, Esq., Sanders Viener Grossman, LLP, Mineola, NY
Gregory Spizer, Esq., Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley, P.C., Philadelphia


  • Summary of the United States Supreme Court and the Virginia State Supreme Court decisions